"The administration is presenting a roadmap for tackling addiction that on paper is laudable, but their own actions—from budget cuts to workforce reductions—actively undermine its potential success. This creates a significant disconnect between stated goals and actual implementation, leaving a sense of instability in the field."
The newly released 195-page National Drug Control Strategy outlines a comprehensive public health approach to the nation’s persistent drug and addiction crisis. The strategy, published on May 4th, articulates a vision that prioritizes making treatment more accessible than illicit drugs, preventing substance use disorders in young people, bolstering support for individuals in recovery, and ultimately reducing the tragic toll of overdose deaths. These overarching objectives have garnered widespread support from public health researchers, addiction treatment professionals, and recovery advocates who see the potential for significant positive impact.
However, a critical concern voiced by many experts is the inherent contradiction between the strategy’s stated public health ambitions and the administration’s own policy decisions. These include substantial layoffs of federal employees, the cancellation of crucial research initiatives, the slashing of community grants, and efforts that undermine harm reduction organizations. Furthermore, significant cuts to Medicaid, the primary payer for addiction and mental health services for millions of low-income Americans, present a formidable obstacle to achieving the strategy’s treatment accessibility goals. This tension between aspirational policy and practical implementation raises serious questions about the strategy’s real-world effectiveness.
Libby Jones, who leads overdose prevention efforts at the Global Health Advocacy Incubator, a public health advocacy group, acknowledges the merits of many components within the National Drug Control Strategy. "Many components of the National Drug Control Strategy are things that we would agree with and that we fully support," Jones stated. However, she quickly pointed out a pervasive issue: "But there are disconnects in what the strategy says is important and then what they’re actually going to fund. Those inconsistencies feel particularly loud in this strategy." This sentiment underscores a growing concern that the administration’s funding priorities and policy actions are not aligned with its stated commitment to addressing the drug crisis.
The National Drug Control Strategy, a document typically released every two years, serves as a cornerstone for coordinating the federal government’s response to a crisis that has profoundly impacted the nation for decades. Since the year 2000, the United States has witnessed an alarming surge in drug overdose deaths, exceeding 1.1 million. While recent data indicates a slight decrease in overdose fatalities, the numbers remain significantly higher than in previous decades. Moreover, research highlights the disproportionate impact of the overdose crisis on Black and Native American communities, underscoring the urgent need for targeted and effective interventions.
The strategy document, which is the first of President Donald Trump’s current term, places a significant emphasis on law enforcement and supply-side interventions, a hallmark of his administration’s approach to addiction. It frequently references an ongoing "war" against drug cartels, referring to them as "foreign terrorist organizations," and highlights increased border enforcement as a key strategy. The document also outlines the implementation of advanced technologies, such as artificial intelligence for screening illicit drugs at the border and wastewater testing for nationwide drug use detection.
Complementing the enforcement-focused measures, the strategy dedicates substantial attention to reducing drug demand through public health initiatives. This includes promoting prevention programs, expanding access to addiction treatment, and fostering robust support networks for individuals in recovery. Notably, the strategy acknowledges the role of religion in the recovery process and advocates for the widespread availability of overdose reversal medications like naloxone. In its official release, the White House Office of National Drug Control Policy described the document as a "roadmap" aimed at "continue dismantling the drug supply and defeating the scourge of illicit drugs in our country."
Despite the comprehensive nature of the strategy, the administration did not provide specific comments on how its various actions align with the document’s stated goals. This lack of clarity adds to the confusion surrounding the administration’s overall approach.
However, there have been some legislative actions that appear to support treatment and recovery. In December, President Trump signed a reauthorization of the SUPPORT Act, which continues funding for various treatment and recovery grants and mandates Medicaid coverage for all FDA-approved medications for opioid use disorder. Furthermore, in January, the administration launched the Great American Recovery Initiative, accompanied by a $100 million investment to address interconnected issues of homelessness, opioid addiction, and public safety.
Despite these positive steps, the details surrounding the Great American Recovery Initiative remain largely unspecified. Adding to the uncertainty, in January, just a month after the SUPPORT Act’s passage, billions of dollars allocated for addiction-related grants were abruptly terminated and then reinstated within a single 24-hour period. This "whiplash," as described by Yngvild Olsen, a national advisor with the Manatt Health consultancy and former SAMHSA leader, created "a sense of instability and uncertainty in the field." Olsen, who served under the Biden administration, departed SAMHSA approximately six months into President Trump’s second term.
This pervasive insecurity has been further exacerbated by the president’s proposed 2027 budget, which includes significant cuts to several addiction and mental health programs and the consolidation of key federal agencies dedicated to these issues. In response, Libby Jones’s group, along with nearly 100 other organizations, has formally requested Congress to reject these proposals, mirroring Congress’s actions on similar requests from the previous year. The newly released national drug strategy thus adds another layer of complexity to an already confusing policy landscape.
Increasing Access to Treatment
A central tenet of the National Drug Control Strategy, emphasized multiple times, is the ambitious goal of making addiction treatment more accessible than illicit drugs. This objective is underscored by stark national data: over 80% of Americans requiring substance use treatment do not receive it, highlighting a critical gap in care. However, the administration’s actions concerning health insurance coverage may significantly impede efforts to improve this statistic.
Medicaid serves as the primary source of healthcare coverage for adults struggling with opioid use disorder. Proposed Medicaid work requirements, part of President Trump’s "One Big Beautiful Bill Act," are projected to eliminate coverage for approximately 1.6 million individuals with substance use disorders. A previous purge of Medicaid rolls, following the expiration of COVID-era protections, resulted in many individuals discontinuing medication treatment for opioid addiction and a decline in new treatment initiations, according to a study published last year.
Dr. Yngvild Olsen, who also practices addiction medicine, expressed support for the strategy’s emphasis on readily available treatment. However, she voiced significant concerns about its practical implementation. "It’s hard to really imagine when now people may have to pay for it themselves because they may be losing their Medicaid insurance coverage," she stated. One analysis estimates that these impending Medicaid changes could lead to 156,000 individuals losing access to essential medications for opioid use disorder, potentially resulting in over 1,000 additional fatal overdoses annually.
The impact may extend beyond Medicaid recipients. The Trump administration has declined to enforce Biden-era regulations designed to strengthen mental health parity, the principle that insurers must cover mental health and addiction treatment comparably to physical health conditions. Furthermore, recent pronouncements indicate a plan to revise these regulations entirely, raising fears of increased unaffordability for addiction treatment. The administration has not provided specific responses to questions about reconciling its Medicaid and parity policies with the stated goal of expanding treatment access.
Prioritizing Prevention
The strategy also highlights the critical importance of preventing addictions before they begin, identifying it as a key component in reducing drug demand. It advocates for promoting a "drug-free America as the social norm" and implementing evidence-based school and community programs. The document emphasizes that "investing in primary prevention, before drug use starts, saves lives and resources," citing studies on the cost-effectiveness of such initiatives.
However, this emphasis on prevention stands in stark contrast to the president’s budget proposals, which include cuts to these very programs. Concurrently, federal layoffs have significantly depleted the agencies responsible for implementing such preventative work. The White House’s most recent budget request for fiscal year 2027 proposes reductions of approximately $220 million from SAMHSA’s Center for Substance Abuse Prevention and nearly $40 million from the Drug-Free Communities program. Since the current administration took office, SAMHSA has lost roughly half of its workforce, and the Centers for Disease Control and Prevention has seen a quarter of its staff depart. "It’s not clear to me that they’re really going to be able to have the funds or the people to be able to carry that out," Olsen commented regarding the strategy’s prevention goals.
An additional point of contention arises in the strategy’s discussion of marijuana. While acknowledging the rising prevalence of marijuana use as a driver of drug use disorders and citing evidence linking cannabis use to an increased risk of psychosis, the strategy calls for developing new tools to treat marijuana withdrawal and addiction. This stance appears at odds with recent administration actions to reclassify medical marijuana to a lower tier of scheduled substances and a forthcoming hearing on rescheduling marijuana more broadly. "The administration, on the one hand, is moving in a direction of liberalizing access to cannabis," Jones observed, "but at the same time, in the strategy, it talks about the dangers of doing so." She further questioned, "There’s a disconnect there that just makes you question: Which one do you believe?" The administration has not responded to specific inquiries regarding its marijuana policies.
Stopping Overdose Deaths
One of the more surprising elements within the National Drug Control Strategy appears in the final chapter, focusing on public drug-checking programs. These programs, often utilizing test strips, enable individuals who use drugs to identify dangerous adulterants like fentanyl or xylazine in their substances, allowing them to make more informed decisions about drug use. The strategy document explicitly states, "Rapid test strips and similar technologies that detect fentanyl and other drugs are an important tool that should be legal."
However, this endorsement is directly contradicted by a recent SAMHSA letter indicating that it would no longer fund test strips, characterizing it as part of the Trump administration’s "clear shift away from harm reduction and practices that facilitate illicit drug use." The administration has also targeted harm reduction programs through an executive order and its budget requests. When asked about the inconsistency between the strategy’s endorsement of drug-checking tools and the withdrawal of funding, the administration offered no comment. Regina LaBelle, a Georgetown University professor and former acting director of the Office of National Drug Control Policy, criticized this contradiction in a blog post, stating, "It is the height of rhetoric over reality to champion a tool while simultaneously cutting off the funding used to acquire it."